The Establishment of Indicators of Thrombocytopenia in Patients Receiving Lenalidomide Therapy

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Multiple myeloma (MM) patients often receive lenalidomide (Len) therapy.
• Thrombocytopenia is a significant side effect of Len treatment.
• Predictive factors for Len-induced thrombocytopenia require further investigation.

Purpose of the Study:

• To analyze the onset of thrombocytopenia and identify related factors in MM patients undergoing Len therapy.
• To determine if pre-treatment platelet (Plt) counts predict the occurrence of significant thrombocytopenia during Len treatment.

Main Methods:

• Retrospective analysis of 28 MM patients receiving Len therapy from July 2010 to March 2014.
• Correlation analysis between pre-treatment Plt counts and minimum Plt counts during therapy.
• Univariate and multivariate analyses to identify factors associated with grade 2 or higher thrombocytopenia.

Main Results:

• A significant correlation was found between pre-treatment Plt count and the nadir Plt count during therapy (r=0.674, p<0.001).
• Pre-treatment Plt count below the normal lower limit (<14.0×10(4)/µL) was a significant factor for grade 2 or higher thrombocytopenia (p=0.011).
• Multivariate analysis identified a Plt count below the normal lower limit as a key prognostic factor (odds ratio: 15.12, p=0.015).

Conclusions:

• A pre-treatment platelet count below the normal lower limit is a significant prognostic factor for developing lenalidomide-induced thrombocytopenia in multiple myeloma patients.
• This finding can inform clinical decisions regarding lenalidomide dosage and monitoring.
• Early identification of at-risk patients may improve treatment outcomes and safety.